Can Bilgen
Department of Plastic Reconstructive and Aesthetic Surgery, Balıkesir University, Turkey.
Indian J Dermatol. 2022 Mar-Apr;67(2):204. doi: 10.4103/ijd.ijd_787_21.
Hyaluronic acid (HA) injections for upper eyelid volumisation are safe procedures with short downtime and low complication rates. Nevertheless, the upper eyelid is a high-risk area for vascular complications because of its rich vascular network. After injection, bruising, an indicator of vascular penetration, develops very often and prolongs the short downtime.
To describe a pain-controlled withdrawal technique for minimizing vascular complications and to examine the effects of topical anaesthesia administered prior to injection on complications related to vascular penetration.
HA was injected into the upper eyelids of 25 patients using the pain-controlled withdrawal technique without topical anaesthesia. The patients' median age, complication rates, average amount of HA administered, and follow-up periods were evaluated. In addition, the patients were asked to evaluate their pain during injection using a numerical pain rating scale.
The patients' mean age was 40.4 ± 7.3 years. Minimal eyelid edema developed in all patients but did not prevent any of the patients' social activities. No bruising was detected in any of the patients, and no major vascular complications, such as blindness or cerebrovascular events, developed. The average amount of HA administered was 1.43 ± 0.45 cc. All patients evaluated their pain during injection as mild.
With the pain-controlled withdrawal technique, none of the patients had minor or major complications due to vascular penetration. The procedure was well tolerated by the patients. The detection of the safe injection zone allowed the administration of more than the standard/accepted 01 cc HA (up to 0.3 cc) from one point.
透明质酸(HA)注射用于上睑容积增加是安全的操作,恢复时间短且并发症发生率低。然而,由于上睑血管网络丰富,是血管并发症的高风险区域。注射后,作为血管穿透指标的瘀斑经常出现,并延长了短暂的恢复时间。
描述一种疼痛控制的退针技术以尽量减少血管并发症,并研究注射前局部麻醉对与血管穿透相关并发症的影响。
使用疼痛控制的退针技术且不进行局部麻醉,将HA注射到25例患者的上睑。评估患者的中位年龄、并发症发生率、HA的平均注射量和随访期。此外,要求患者使用数字疼痛评分量表评估注射期间的疼痛。
患者的平均年龄为40.4±7.3岁。所有患者均出现轻微的眼睑水肿,但未妨碍任何患者的社交活动。所有患者均未检测到瘀斑,也未发生任何重大血管并发症,如失明或脑血管事件。HA的平均注射量为1.43±0.45 cc。所有患者均将注射期间的疼痛评估为轻度。
采用疼痛控制的退针技术,没有患者因血管穿透出现轻微或重大并发症。该操作患者耐受性良好。安全注射区域的确定使得从一个点注射的HA量超过标准/公认的0.1 cc(可达0.3 cc)。